D-0690-2018 Class II Terminated

Recalled by Time-Cap Laboratories, Inc. — Farmingdale, NY

FDA drug recall D-0690-2018 was initiated by Time-Cap Laboratories, Inc. on Jan 11, 2018 and is designated Class II. Reason for recall: CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies. The recall status is terminated (terminated Jan 20, 2021).

Recall details

Product Type
Drugs
Report Date
May 2, 2018
Initiation Date
Jan 11, 2018
Termination Date
Jan 20, 2021
Voluntary/Mandated
Voluntary: Firm initiated

Product description

Ibuprofen Tablets USP 600 mg, a) 100 tablets (NDC 42582-112-10) and b) 500 tablet bottles (NDC 42582-112-18), Rx, Distributed by: Bi-Coastal Pharma International, Shrewsbury, NJ, Manufactured by: Marksans Pharma, Ltd., Plot No. L-82, L-83 Verna indl. Estate Verna, Goa-403 722, India

Reason for recall

CGMP Deviations: Various strengths of ibuprofen tablets/caplets are being recalled due to complaints of odor related to CGMP deficiencies.

Distribution pattern

Nationwide.

Code information

a) D044C, D038C, D043C, exp 3/18, b) C136C, exp 3/18, D039C, D040C, D041C, D042C, 3/18

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0690-2018
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0690-2018. Report a data issue: hello@regdatalab.com.